Nine out of 10 clinical trials worldwide can’t recruit enough people within their target timeframes.

Some trials fail altogether for lack of enough participants.

What if researchers didn’t need to recruit a control group at all and could offer the experimental treatment to everyone who agreed to be in the study? Celsion, a biotechnology company that develops next-generation chemotherapy and immunotherapy agents, is exploring such an approach with Medidata.

Download this white paper, in partnership with MIT Technology Review, to learn how Celsion leverages Medidata’s detailed information from 23,000+ trials and 7 million patients to create “external control arms” and speed up the clinical trial process.